What's Happening?
Faeth Therapeutics has announced results from the Phase 2 DICE trial, which evaluated the combination of sapanisertib and paclitaxel in women with platinum-resistant ovarian cancer. The trial showed a 34%
reduction in the risk of disease progression compared to paclitaxel alone, with a mean progression-free survival of 5.8 months. The study met its primary endpoint, supporting the advancement to a Phase 3 trial. The combination therapy was associated with manageable adverse events, including gastrointestinal toxicities and rash.
Why It's Important?
The DICE trial results are significant as they offer a potential new treatment option for women with platinum-resistant ovarian cancer, a condition with limited effective therapies. The findings suggest that targeting cancer cell metabolism can enhance the efficacy of existing treatments, potentially leading to improved patient outcomes. This advancement highlights the importance of precision medicine and the integration of targeted therapies in oncology.
What's Next?
Faeth Therapeutics plans to advance the combination of sapanisertib and paclitaxel to a Phase 3 trial, aiming to confirm the efficacy and safety observed in the Phase 2 study. The company is also exploring the combination's potential in other cancer types, including endometrial and breast cancer. Ongoing biomarker analyses will help identify patients most likely to benefit from the therapy, further personalizing treatment approaches.
